Complex | |
AACDB_ID: | 3595 |
PDBID: | 7DF1 |
Chains: | E_I |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.81 |
Reference: | 10.1038/s41551-022-00956-5 |
Antibody | |
Antibody: | S1-F4 scFv |
Antibody mutation: | No |
INN (Clinical Trial): | |
Antigen | |
Antigen: | human CD98 complex |
Antigen mutation: | No |
Durg Target: |
Antibody
Chain: E
Mutation: NULL
>7DF1_E|Chain E, G[auth F], I[auth G], K[auth H]|S1-F4 VH|Homo sapiens (9606) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGYYDILTGSRPIFFDIWGQGTMVTVSSGGGGSGGGGSGGGGS |
Antigen
Chain: I
Mutation: NULL
>7DF1_I|Chain F[auth I], H[auth J], J[auth K], L|IGL c2062_light_IGKV4-1_IGKJ5|Homo sapiens (9606) DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYNTPITFGQGTRLEIKAAAHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
E: VAL37 GLN39 GLN43 GLY44 LEU45 GLU46 TRP47 SER58 TYR59 ALA60 GLN61 TYR91 TYR96 ASP98 PHE100 ASP101 TRP103 GLY104 GLN105 I: LYS30 TYR32 ALA34 TYR36 GLN38 GLY41 GLN42 PRO43 PRO44 LEU46 TYR49 TRP50 GLU55 TYR87 GLN89 TYR91 THR94 PRO95 ILE96 PHE98 GLY99 GLN100 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)